1Early Breast Cancer Trialists Conaborative Group. Tamoxifen for early breast cancer. Cochrane Database Syst Rey, 2001 ; 1 : 486.
2Will BP, Nobrega KM, Berthelot JM. First do no harm: extending the debate on the provision of preventive tamoxifen. Br J Cancer, 2001 ; 85 :1280-1288.
3Kardinal CG, Veith R. Prevention of breast cancer in high-riskwomen. J La State Med Soc, 1999; 151: 198-201.
4Gerber B, krause A, Muller H. Effects of adjuvant tamoxifen on the endometrium in postmenopausal women with breast cancer: a prospective long-term study using transvaginal ultrasound. J Clin Oncol , 2000; 18:3464-3470.
5Zarbo G, Caruso G, Zammitti M. The effects of tamoxifen therapy on the endometrium. Ear J Cynaecol Oncol , 2000; 21: 86-88.
6Tesore MR, Borgida AF, MacLaurin NA. Transvaginal endometrial sonography in postmenopausal women taking tamoxifen. Obstet Gynecol,1999; 93: 363-366.
7Cohen I, Perel E, Tepper M. Dose-dependent effect of tamoxifen therapy on endometrial pathologies in postmenopausal breast cancer parents. Breast cancer Res Treat, 1999; 53: 255-262.
8Meier CR, Jick H. Tamoxifen and risk of idiopathic venous thromboembolism. Br J Clin Pharmacol, 1998; 45: 608-612.
9Nomura Y, Nakajima M, Tominaga T. Late phase Ⅱ study of TAT-59 (miproxifene phospate) in advanced or recurrent breast cancer patients (a double-blind comparative study with tamoxifen citrate). Gan To Kagaku Ryoho, 1998; 25: 1045-1063.
10Broniscer A, Leite CC, Lanchote VL. Radiation therapy and high-dose tamoxifen in the treatment of patients with diffuse brainstem gtiomas: results of a Brazilian cooperative study. Brainstem Glioma Cooperative Group. J Clin Oncol, 2000; 18: 1246-1253.
